** Shares of drugmaker Biogen BIIB.O rise 2.8% to $118.42
** BIIB says that the final process for the European Commission's decision on the marketing authorization application for the company's Alzheimer's drug lecanemab is underway
** The update comes after the reconfirmation of the positive opinion for the drug's approval by the Committee for Medicinal Products for Human Use $(CHMP)$ in February 2025
** The therapy, already approved in U.S. and many other countries, could become Europe's first drug approved to treat the neurodegenerative condition directly rather than just its symptoms
** As of last close, stock has fallen 23.1% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。